Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:23 PM
Ignite Modification Date:
2025-12-24 @ 9:23 PM
NCT ID:
NCT05966532
Eligibility Criteria:
Inclusion Criteria:
1. Male and female participants
2. Age between 21-80 years old
3. DSM-5 diagnosis of major depressive disorder (MDD) based on Mini Neuropsychiatric Interview
4. Inventory of Depressive Symptomatology-Clinician Rated version (IDS-C) total score \> 14
5. Able to read, write, and comprehend English
6. Provide informed consent; willing to comply with study protocol
Exclusion Criteria:
1. History of bipolar disorder, schizophrenia, or schizoaffective disorder
2. Presence of psychotic features
3. Lifetime central nervous system (CNS) disease (including head injury with loss of consciousness \> 5 minutes)
4. History of neurodevelopmental disorder (e.g., Autism spectrum disorder)
5. History of medical conditions that can affect neurocognitive function as well as be confounded with age (e.g., thyroid disease, endocrine illnesses)
6. Women who are pregnant
7. Current use of medications with known impacts on neurocognitive function (e.g., acetylcholinesterase inhibitors, amphetamine, methylphenidate, vortioxetine, sedatives)
8. Alcohol/substance use disorder within past 3 months
9. DSM-5 diagnosis of major cognitive impairment
10. Current sensory or physical impairment that interferes with testing.
11. Contraindication to MRI and MEG (only for depressed participants) (e.g., any electronic / metallic implants near or within the head or body, claustrophobia)
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
21 Years
Maximum Age:
80 Years
Study:
NCT05966532
Study Brief:
Protocol Section:
NCT05966532